Are you a runner? Please join our #Run4HepB team and make your miles matter at the NYC Marathon on November 3! Learn more.



News and Updates

Current News

Investigating Hepatitis B Virus-Related Hepatocellular Carcinoma Incidence

Hepatocellular carcinoma immune microenvironment and check point inhibitors-current status

Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives

UAB Medicine Podcast: Multi-Disciplinary Hepatocellular Carcinoma Clinic (HCC)

Clinical and Epidemiological Aspects of Hepatocellular Carcinoma at the Internal Medicine Department of Point “G” Teaching Hospital in Mali

Insights into Hepatocellular Carcinoma: From Pathophysiology to Novel Therapies

FPU2023- Targeting the microenvironment in liver cancer

Old Vaccine Potentially Treats Liver Cancer

AFP L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation

Telomerase-related advances in hepatocellular carcinoma: A bibliometric and visual analysis

3D Contrast-Enhanced Ultrasound in Diagnosing Participants with Liver Cancer Undergoing Stereotactic Ablative Radiotherapy

Adding Immunotherapy to Local Treatment Delays Liver Cancer Progression

Global burden of liver cirrhosis and other chronic liver diseases caused by specific etiologies from 1990 to 2019

RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma 

Design, Synthesis, and Anti-Hepatocellular Carcinoma Evaluation of Sesquiterpene Lactone Epimers Trilobolide-6-O-isobutyrate Analogs

Computational-guided approach for identification of PI3K alpha inhibitor in the treatment of hepatocellular carcinoma by virtual screening and water map analysis

Targeting metalloproteases is a promising strategy to enhance immunotherapy responses by overcoming immune exclusion in hepatocellular carcinoma

Network-based pharmacology-based research on the effect and mechanism of the Hedyotis diffusa–Scutellaria Barbata pair in the treatment of hepatocellular carcinoma

Construction and validation of a novel lysosomal signature for hepatocellular carcinoma prognosis, diagnosis, and therapeutic decision-making

Clinical manifestation, staging and prognosis of hepatocellular carcinoma in Gambian patients

Incidence of Etiology-specific Hepatocellular Carcinoma: diverging trends and significant heterogeneity by race and ethnicity

NCCN 2023 Liver Cancer Guidelines for Patients

Gene mutations linked to drug-resistant liver cancer

Complementary and Alternative Medicine

A Novel Online Calculator Based on Serum Biomarkers to Detect Hepatocellular Carcinoma among Patients with Hepatitis B

Management of Hepatocellular Carcinoma

BAIAP2L2 is a Novel Prognostic Biomarker Related to Migration and Invasion of HCC and Associated with Cuprotosis

Advancing the Care of Advanced HCC – A Hepatologist’s Perspective

Novel Use of Artificial Intelligence Shows Promise to Improve HCC Detection

Molecular and Clinical Features of Hepatocellular Carcinoma in Patients with HBV-HDV Infection

Genentech’s Tecentriq Plus Avastin Reduced the Risk of Cancer Returning in People With Certain Types of Adjuvant Liver Cancer in a Phase III Study

Review of insights into the success and failure of systemic therapy for liver cancer

REACH-B Score for Hepatocellular Carcinoma

Minimally-invasive surgical options for liver cancer and liver tumors, and other options from the multidisciplinary team from Johns Hopkins (Video)

About Herbs, Botanicals, and Other Products (from Memorial Sloan Kettering Cancer Center)

Four Liver Cancer Treatment Advances 

Pan Tumor Clinical Trial Is Actively Recruiting to Investigate the Effects of Nivolumab When Given Under the Skin With or Without rHuPH20. Learn more! 

Assessing the Risk of HCC for Hepatitis B Treatments

Study Uncovers New Treatment Approaches for Liver Cancer Patients

NUS Scientists Discover New Clues to Liver Cancer Progression

Cancer survivors: Managing your emotions after cancer treatment

Researchers Identify a New tsRNA in Blood to Improve Liver Cancer Diagnosis

Case 3: Novel Frontline Combination Strategies for Unresectable HCC (Video)

News Archive

What Gastroenterologists Need to Know About New Guidelines on Systemic HCC Therapy

Bringing Early Cancer Detection to the Masses

The Cancer Experience Registry is an online survey that allows people facing cancer to share their experiences, identify the issues that impact their life, and help them understand their experiences.

Dr. Gish talks about the importance of liver cancer surveillance and the blood work and imaging involved in regular monitoring - all in less than 2 minutes (Video)

What Cancer Survivors Should Know About Their Mental Health

Antiviral therapy improves survival among elderly patients after hepatectomy for hepatitis B virus (HBV)–related hepatocellular carcinoma (HCC)

AstraZeneca’s immunotherapy tremelimumab has secured its first FDA approval and is to be sold under the brand name Imjudo

FDA approves a combination of the immunotherapy drugs durvalumab (Imfinzi®) plus the experimental drug tremelimumab for people with unresectable hepatocellular cancer, the most common type of liver cancer

Evidence Grows for Avoiding Biopsy in Hepatocellular Carcinoma

New Guidelines Clarify Use of Systemic Therapy in Advanced HCC

After FDA Evaluation, BMS Withdraws Opdivo For Liver Cancer Treatment in Patients Previously Treated with Sorafenib in the U.S.

FDA Grants “Orphan Drug” Designation to Chemotherapeutic Uttroside-B for Use in Patients with HCC. The drug is in pre-clinical testing.

COVID-19: What People With Cancer Need to Know (, June 2020)

FDA Approves Atezolizumab Plus Bevacizumab for Patients With Unresectable or Metastatic Hepatocellular Carcinoma 

Atezolizumab Combination Improves Survival in HCC (Cancer Letter, May 2020)

U.S. FDA Approves Opdivo® (Nivolumab) + Yervoy® (Ipilimumab) for Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib

U.S. Food and Drug Administration (FDA) Has Granted Breakthrough Device Designation to the Elecsys® GALAD Score to Help Diagnose HCC

FDA Has Approved Cabozantinib (CABOMETYX, Exelixis, Inc.) for Patients with Hepatocellular Carcinoma Who Have Been Previously Treated with Sorafenib

DNA Search Finds People Resistant to Liver Disease. Can We Mimic This Effect with a Drug? Regeneron and Alnylam Pharmaceutical to Partner  

Newly Discovered Anti-Cancer Protein LHPP Prevents Uncontrolled Proliferation of Cancer Cells in the Liver and May Serve as a Biomarker for the Diagnosis & Prognosis of Liver Cancer 

New Point-of-Care Ultrasound Tool May Aid Detection of Liver Stiffness in Obese Patients

Phase II Trial of GT90001 Plus Nivolumab Enrolls First Patient with Advanced HCC

Treatment of Hepatocellular Carcinoma in Sub-Saharan Africa: Challenges and Solutions

Kintor Initiates Dosing in Phase II Hepatocellular Carcinoma Therapy Trial

How Have Hepatocellular Carcinoma Treatments Improved?

Neoadjuvant Immunotherapy for Resectable Hepatocellular Carcinoma

Hepion Pharmaceuticals Receives FDA Orphan Drug Status Designation for Rencofilstat for the Treatment of HCC

Perioperative Opdivo Alone, in Combination with Yervoy, Safe for Patients with HCC

Omega Therapeutics Announces FDA Clearance of IND Application for OTX-2002, First Omega Epigenomic Controller, for MYC Driven Hepatocellular Carcinoma

AACR Report Finds Racial and Ethnic Minorities Continue to Shoulder a Disproportionate Burden of Cancer

Cabozantinib Plus Atezolizumab in Advanced Hepatocellular Carcinoma and the Role of Adjuvant Antiviral Therapy

Phase III Trial of Cabozantinib and Atezolizumab vs Sorafenib in Advanced Hepatocellular Carcinoma

Elevar Therapeutics and Hengrui Pharma Announce Camrelizumab Plus Rivoceranib Significantly Prolonged Overall Survival and Progression-Free Survival in Patients With Unresectable Hepatocellular Carcinoma (Phase III Trial)

New Study Shows Options for Older Patients With Liver Cancer

Novartis and BeiGene have announced new data from a phase 3 trial that shows tislelizumab demonstrated non-inferior overall survival (OS) compared to sorafenib in patients with previously untreated, unresectable hepatocellular carcinoma

Dr Reddy’s Laboratories announces the launch of Dr Reddy’s Sorafenib Tablets, USP, 200 mg, a therapeutic generic equivalent of Nexavar (sorafenib) Tablets in the US market following the approval by the US Food and Drug Administration

JW Therapeutics announces the initiation of phase I clinical study of JWATM204 in patients with advanced hepatocellular carcinoma

The International Liver Cancer Network (ILCN), of which HBF is a member, released a white paper promoting increased effort to improve prevention, early detection and access to care for liver cancer.

Cancer Burden Facing Asian Americans Partly Caused By Racism